一项评估奥瑞珠单抗在复发缓解型多发性硬化症和原发进展型多发性硬化症参与者中的疗效、安全性、药代动力学及药效学的研究
一项在中国复发型多发性硬化症和原发性进展型多发性硬化症患者中评估奥瑞珠单抗疗效、安全性、药代动力学和药效学的多中心、开放标签、单臂研究
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).
研究概览
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Beijing、中国、100034
- Peking University First Hospital
-
Beijing、中国、100032
- Peking Union Medical College Hospital
-
Beijing、中国、100730
- Beijing Hospital of Ministry of Health
-
Changsha、中国、410008
- Xiangya Hospital Central South University
-
Chengdu、中国、610041
- West China Hospital of Sichuan University
-
Chongqing、中国、400016
- The First Affiliated Hospital, Chongqing Medical University
-
Guangzhou、中国、510080
- The First Affiliated Hospital of Sun Yat-sen University
-
Guangzhou、中国、510630
- The Third Affiliated Hospital of Sun Yat-Sen University
-
Hangzhou、中国、310003
- The First Affiliated Hospital of College of Medicine, Zhejiang University
-
Hohhot、中国、010011
- Inner Mongolia Autonomous Region People's Hospital
-
Lanzhou、中国、730030
- Lanzhou University Second Hospital
-
Shenyang、中国、DUMMY_VALUE
- The First Hospital of China Medical University
-
Shijiazhuang、中国、050000
- The Second Hospital of Hebei Medical University
-
Taiyuan、中国、030000
- 1st Affiliated Hospital of Shanxi Medical University
-
Wuhan、中国、430030
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
-
Ürümqi、中国、830000
- Xinjiang People Hospital
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330209
- The First Affiliated Hospital of Nanchang University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Diagnosis of RMS/PPMS in accordance with the revised 2017 McDonald Criteria
- EDSS score from 0-5.5 (RMS) or 3.0-6.5 (PPMS), inclusive, at screening and baseline
- Documented MRI of brain with abnormalities consistent with MS before screening
Exclusion Criteria:
- Diagnosis of PPMS or non-active secondary progressive multiple sclerosis (SPMS) (only for RMS cohort)
- History of relapsing remitting multiple sclerosis (RRMS) or SPMS at screening (only for PPMS cohort)
- Disease duration of more than 10 years in participants with an EDSS ≤ 2.0 at screening (only for RMS cohort)
- History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
- Inability to complete an MRI scan or contraindication to Gd administration
- Contraindications to mandatory pre-medications (i.e., corticosteroids and antihistamines)
- Known presence of other neurologic disorders if they could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- Known history of human immunodeficiency virus (HIV) infection
- Lack of peripheral venous access
- Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab), unless the last infusion was at least 6 months prior to screening
- Positive screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:RMS Cohort
Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
其他名称:
|
|
实验性的:PPMS Cohort
Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
RMS队列:年化方案定义的复发率
大体时间:最长约1.6年
|
最长约1.6年
|
|
PPMS队列:血液中的B细胞水平
大体时间:至第 48 周
|
至第 48 周
|
|
PPMS队列:第48周时达到分化簇19(CD19+)B细胞水平低于10个细胞/微升(μL)的参与者百分比
大体时间:第48周时
|
第48周时
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
RMS队列:在48周期间内无疾病活动证据(NEDA3)的参与者百分比
大体时间:最长至第48周
|
最长至第48周
|
|
|
RMS队列:第48周无复发参与者的百分比
大体时间:至第48周
|
至第48周
|
|
|
RMS队列:在24周期间实现NEDA3的参与者百分比
大体时间:直至第24周
|
直至第24周
|
|
|
RMS队列:通过脑部磁共振成像(MRI)检测到的T1钆(Gd)增强病变总数
大体时间:截至第48周
|
截至第48周
|
|
|
RMS队列:通过脑部MRI检测到的新发或扩大的T2高信号病灶总数
大体时间:截至第48周
|
截至第48周
|
|
|
RMS和PPMS队列:从基线至第48周血清神经丝轻链(Nfl)浓度的变化
大体时间:基线至第48周
|
基线至第48周
|
|
|
RMS 和 PPMS 队列:奥瑞珠单抗血清浓度
大体时间:至第48周
|
至第48周
|
|
|
RMS 队列:血液中的 B 细胞水平
大体时间:截至第48周
|
截至第48周
|
|
|
RMS队列:第48周时达到CD19+ B细胞水平<10个细胞/μL的参与者百分比
大体时间:在第48周
|
在第48周
|
|
|
PPMS队列:通过脑部MRI检测到的第24周和第48周T1钆增强病灶总数
大体时间:第24周和第48周
|
第24周和第48周
|
|
|
PPMS队列:脑部MRI在第24周和第48周检测到的新发或扩大的T2高信号病灶总数
大体时间:第24周和第48周
|
第24周和第48周
|
|
|
RMS和PPMS队列:出现不良事件(AEs)的参与者人数
大体时间:最多约1.8年
|
最多约1.8年
|
|
|
RMS和PPMS队列:T细胞水平相对基线的变化
大体时间:最长约1.8年
|
最长约1.8年
|
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)
大体时间:Baseline up to Week 48
|
EDSS is a scale for assessing neurologic impairment in participants with multiple sclerosis (MS). EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral [or mental]) that are rated and then scored as a functional systems scores (FSS), and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale ranging from 0 to 5 or 6 and an ambulation score that is rated from 0 to 16. These ratings are then used in conjunction with observations, as well as information, concerning ambulation and use of assistive devices to determine the total EDSS score. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)
大体时间:Baseline up to Week 48
|
The T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant is directed to start at one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly and safely as possible and immediately walk back the same distance. Score for the T25FWT is the average of the two completed trials. The time taken to complete the test is measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. A 20% change from baseline of the averaged T25FWT is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)
大体时间:Baseline up to Week 48
|
The 9-HPT is a performance measure used to assess upper extremity (arm and hand) function. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time indicates higher raw scores, which indicates deterioration. A 20% change from baseline is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48
大体时间:Baseline, Week 48
|
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. |
Baseline, Week 48
|
|
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Up to approximately 1.8 years
|
C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior. |
Up to approximately 1.8 years
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- YN44938
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.